NLRP3 activation induces ASC-dependent programmed necrotic cell death, which leads to neutrophilic inflammation.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Satoh T;Satoh T; Kambe N; Matsue H
  • Source:
    Cell death & disease [Cell Death Dis] 2013 May 23; Vol. 4, pp. e644. Date of Electronic Publication: 2013 May 23.
  • Publication Type:
    Journal Article; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101524092 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-4889 (Electronic) NLM ISO Abbreviation: Cell Death Dis Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : Nature Pub. Group
    • Subject Terms:
      Apoptosis*/drug effects ; Inflammation* ; Necrosis*; Carrier Proteins/*metabolism ; Cytoskeletal Proteins/*metabolism; Amino Acid Chloromethyl Ketones/pharmacology ; Animals ; Apoptosis Regulatory Proteins ; CARD Signaling Adaptor Proteins ; Carrier Proteins/genetics ; Caspase 1/chemistry ; Caspase 1/genetics ; Caspase 1/metabolism ; Caspase Inhibitors/pharmacology ; Cytoskeletal Proteins/antagonists & inhibitors ; Cytoskeletal Proteins/genetics ; Dipeptides/pharmacology ; Doxycycline/pharmacology ; Humans ; Interleukin-1beta/metabolism ; Mice ; NLR Family, Pyrin Domain-Containing 3 Protein ; Neutrophils/cytology ; Neutrophils/immunology ; Neutrophils/metabolism ; RNA Interference ; RNA, Small Interfering/metabolism
    • Abstract:
      NLR family pyrin domain containing 3 (NLRP3) is a cytoplasmic pattern recognition receptor that regulates innate immune responses by forming a protein complex, the inflammasome. It leads to production of proinflammatory cytokine productions such as interleukin 1β (IL-1β). We and others demonstrated that an induction of activated NLRP3 also induced cell death. However, little is known about the characteristics and mechanisms of the cell death and its involvement in the pathogenesis of inflammatory conditions. In this study, we established cell lines in which NLRP3 was induced by doxycycline using a tetracycline-inducible expression (Tet-on) system. Using this system, the expression of NLRP3 mutants in cryopyrin-associated periodic syndrome (CAPS) patients was sufficient for the induction of necrotic cell death without lipopolysaccharide stimulation or generation of mature IL-1β. We also found that CA074-Me, a cathepsin B inhibitor, blocked cell death before oligomerization of apoptosis-associated speck-like protein containing a CARD (ASC), whereas Z-VAD-fmk, a pan-caspase inhibitor, blocked the cell death after the oligomerization. Silencing of the ASC gene (Pycard) by small hairpin RNA treatment inhibited the NLRP3 mutant-induced cell death, but silencing of the caspase-1 gene (Casp1) did not. Taken together, these results indicated that ASC was indispensable for NLRP3-mediated programmed necrotic cell death, and that this type of cell death was distinct from 'pyroptosis', which requires caspase-1. Finally, we demonstrated in an in vivo model that the programmed necrotic cell death induced by activated NLRP3 could cause neutrophil infiltration, indicating a possible role of cell death in neutrophil infiltration of skin lesions in CAPS patients.
    • References:
      N Engl J Med. 2009 Jun 4;360(23):2438-44. (PMID: 19494219)
      Nat Immunol. 2011 Mar;12(3):222-30. (PMID: 21151103)
      Blood. 2007 Apr 1;109(7):2903-11. (PMID: 17164343)
      J Biol Chem. 2012 Mar 23;287(13):10650-10663. (PMID: 22235111)
      Cell Death Differ. 2003 Sep;10(9):956-68. (PMID: 12934070)
      J Exp Med. 2009 May 11;206(5):1037-46. (PMID: 19364881)
      Nat Immunol. 2010 May;11(5):385-93. (PMID: 20351693)
      Cell Host Microbe. 2007 Sep 13;2(3):147-59. (PMID: 18005730)
      Nature. 2002 Jul 11;418(6894):191-5. (PMID: 12110890)
      J Biol Chem. 2011 Jun 17;286(24):21844-52. (PMID: 21525001)
      Mol Microbiol. 2000 Oct;38(1):31-40. (PMID: 11029688)
      Proc Natl Acad Sci U S A. 2010 May 25;107(21):9771-6. (PMID: 20457908)
      J Immunol. 2009 May 15;182(10):6460-9. (PMID: 19414800)
      Nat Immunol. 2008 Aug;9(8):847-56. (PMID: 18604214)
      Nature. 2006 Jul 6;442(7098):39-44. (PMID: 16823444)
      Biochim Biophys Acta. 2012 Jan;1824(1):68-88. (PMID: 22024571)
      Clin Exp Dermatol. 2008 Jan;33(1):1-9. (PMID: 17927785)
      Blood. 2008 Feb 15;111(4):2132-41. (PMID: 18063752)
      PLoS Pathog. 2007 Nov;3(11):e161. (PMID: 17983266)
      Ann Rheum Dis. 1986 Oct;45(10):873-7. (PMID: 3789822)
      Nat Immunol. 2008 Aug;9(8):857-65. (PMID: 18604209)
      Nat Immunol. 2010 May;11(5):395-402. (PMID: 20351692)
      Cell Death Differ. 2007 Sep;14(9):1590-604. (PMID: 17599095)
      Curr Opin Immunol. 2004 Feb;16(1):48-62. (PMID: 14734110)
      Plant J. 2007 Oct;52(1):1-13. (PMID: 17697096)
      Nat Genet. 2001 Nov;29(3):301-5. (PMID: 11687797)
      J Immunol. 2010 Oct 1;185(7):4385-92. (PMID: 20802146)
      Immunity. 2004 Mar;20(3):319-25. (PMID: 15030775)
      Nat Rev Immunol. 2010 Mar;10(3):210-5. (PMID: 20168318)
      Cell Microbiol. 2001 Dec;3(12):825-37. (PMID: 11736994)
      Cell. 2006 Feb 24;124(4):803-14. (PMID: 16497589)
    • Accession Number:
      0 (Amino Acid Chloromethyl Ketones)
      0 (Apoptosis Regulatory Proteins)
      0 (CA 074 methyl ester)
      0 (CARD Signaling Adaptor Proteins)
      0 (Carrier Proteins)
      0 (Caspase Inhibitors)
      0 (Cytoskeletal Proteins)
      0 (Dipeptides)
      0 (Interleukin-1beta)
      0 (NLR Family, Pyrin Domain-Containing 3 Protein)
      0 (Nlrp3 protein, mouse)
      0 (Pycard protein, mouse)
      0 (RNA, Small Interfering)
      0 (benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone)
      EC 3.4.22.36 (Caspase 1)
      N12000U13O (Doxycycline)
    • Publication Date:
      Date Created: 20130525 Date Completed: 20131023 Latest Revision: 20211021
    • Publication Date:
      20250114
    • Accession Number:
      PMC3674376
    • Accession Number:
      10.1038/cddis.2013.169
    • Accession Number:
      23703389